Small molecule, big difference: the GLP-1 pill problem was never the receptor

Semaglutide and tirzepatide are effective weight loss drugs. But both require injections because your gut would break these drugs down like food if you took them as pills.

On August 10, Structure Therapeutics published Phase 2b results in Nature Medicine for a once daily pill that engages the same receptor. The interesting part is what kind of molecule it is.

Aleniglipron was tested against placebo in 230 adults with overweight or obesity across 38 US centres. Doses escalated every four weeks over 36 weeks. Placebo adjusted weight reduction came in at 8.2%, 9.8% and 11.3% for the 45, 90 and 120 mg arms respectively. Total reduction on the top dose reached roughly 12%.

The responder figures matter more than the average. On 120 mg, 86% of participants lost at least 5% of body weight, 70% lost at least 10%, and 38% lost at least 15%. Side effects followed the familiar GLP-1 pattern: nausea and vomiting. They were milder in the arms that started lower and titrated up slowly.

A peptide is a short chain of amino acids. Swallow one and it meets the same machinery that dismantles a steak. Acid in the stomach, then proteases in the small intestine that cut peptide chains apart on contact. Whatever survives still has to cross the gut wall, and peptides are large and water loving, which is precisely what that barrier is built to exclude.

Novo Nordisk solved this once, with oral semaglutide, by co-formulating it with an absorption enhancer and requiring patients to take it fasted with a small sip of water and then wait. It works, but bioavailability stays in the low single digits. Most of each expensive dose is destroyed.

Aleniglipron is not a peptide. It is a conventional small molecule, built to fit the GLP-1 receptor without imitating the natural hormone’s structure. Small molecules are compact, chemically stable and largely indifferent to proteases. That is why most of the medicines in your bathroom cabinet are tablets.

The second consequence is industrial. Peptides are grown, through fermentation or solid phase synthesis, in facilities that take years to build. That is the real reason the injectables spent two years in shortage. Small molecules are made in chemical reactors, cheaply and at enormous scale. If a pill this effective reaches market, the constraint on supply stops being manufacturing capacity and starts being who can pay.

For comparison, Eli Lilly’s oral small molecule orforglipron reported 12.4% total weight loss over 72 weeks. Aleniglipron reached roughly 12% in half that time. The trials differ in population, dosing and design, so cross trial comparison is always shaky. This is Phase 2b in 230 people. The tolerability question that decides oral GLP-1s is whether patients stay on them, and 36 weeks is not long enough to answer it.